Ensign Peak Advisors
JBIO

Ensign Peak Advisors’s Jade Biosciences JBIO Stock Holding History

Ensign Peak Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,493
Closed -$7.75M – 1715
2024
Q1 		$7.75M Buy
7,493
+4,000
+115% +$3.06M 0.01% 513
2023
Q4 		$2.77M Buy
3,493
+3,064
+714% +$1.56M 0.01% 792
2023
Q3 		$204K Hold
429
– – ﹤0.01% 1725
2023
Q2 		$257K Hold
429
– – ﹤0.01% 1726
2023
Q1 		$303K Sell
429
-177
-29% -$147K ﹤0.01% 1713
2022
Q4 		$621K Buy
+606
New +$440K ﹤0.01% 1536

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return